Currency In USD
| Previous Close | 1.94 |
| Open | 1.95 |
| Day High | 1.99 |
| Day Low | 1.91 |
| 52-Week High | 6.44 |
| 52-Week Low | 1.9 |
| Volume | 2.04M |
| Average Volume | 3.89M |
| Market Cap | 378.34M |
| PE | -2.49 |
| EPS | -0.78 |
| Moving Average 50 Days | 2.67 |
| Moving Average 200 Days | 3.18 |
| Change | 0.01 |
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
GlobeNewswire Inc.
Feb 26, 2026 12:30 PM GMT
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 202
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 29, 2026 10:54 PM GMT
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced register
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 28, 2026 2:25 AM GMT
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purc